Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study
Launched by YALE UNIVERSITY · Jan 21, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how cocaine use affects the brain by measuring something called synaptic density, which refers to the connections between brain cells. Researchers want to compare individuals who have cocaine use disorder with healthy individuals who do not use cocaine. The goal is to learn more about how cocaine changes brain function, which could help develop better treatments for those struggling with addiction.
To participate in this study, you need to be between 21 and 60 years old and in good physical health. If you're a woman, you'll need to have a negative pregnancy test. People with cocaine use disorder must show signs of recent use, while healthy controls must not have used cocaine or other drugs. Participants will undergo various medical tests, including brain imaging, to help researchers gather the information they need. If you're interested in contributing to our understanding of cocaine addiction and its effects on the brain, this trial might be a great opportunity for you!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 21-60 years
- • Physically healthy by medical history, physical, neurological, ECG and laboratory examinations
- • For females, a negative serum pregnancy test
- • For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use
- • For HC: Negative urine toxicology
- Exclusion Criteria:
- • DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine
- • A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)
- • A history of significant and/or uncontrolled medical or neurological illness
- • Current use of psychotropic and/or potentially psychoactive prescription medications
- • Medical contraindications to MRI procedure
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Trial Officials
Gustavo Angarita, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials